The bill authorizes the commissioner of human services in Minnesota to provide separate reimbursement for biological products used in inpatient hospital settings as part of cell or gene therapy for treating rare diseases. This new provision, added as subdivision 32 to Minnesota Statutes 2022, section 256.969, allows hospitals to receive additional payment beyond the standard diagnostic related group reimbursement for inpatient admissions where such therapies are administered.

Furthermore, the commissioner is tasked with establishing the reimbursement rate for these biological products based on existing methodologies for outpatient drug administration. The bill also mandates that managed care and county-based purchasing plans comply with these reimbursement requirements for medical assistance enrollees, ensuring that the reimbursement level meets or exceeds the rate set by the commissioner. The provisions of this bill are set to take effect on January 1, 2025.

Statutes affected:
Introduction: 256.969